RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Terns Pharma, a Silicon Valley-Shanghai company, started a US Phase I clinical trial of TERN-101 to treat non-alcoholic steatohepatitis (NASH). TERN-101 is a farnesoid X receptor (FXR) agonist. One year ago, Terns in-licensed three drug candidates from Eli Lilly, including TERN-101. At the same time, the company announced it had received $30 million in start-up capital from Lilly Asia Ventures. Terns focuses on molecularly-targeted drugs and combination therapies that treat liver diseases and liver cancer.
Source: China Biotoday
